Heparin resistance

Laboratory Hematology

Volumn 9, Issue 3, 2003, Pages 125-131

  Bharadwaj, Jayaram ^a   Jayaraman, Chandrasekhar ^b   Shrivastava, Rakesh ^a  

^a UNITY HEALTH SYSTEM   (United States)

^b LENOX HILL HOSPITAL   (United States)

Author keywords

Antithrombin III; Heparin resistance; Recurrent thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE; APROTININ; BLOOD CLOTTING FACTOR 8; DANAZOL; DEXTRAN; DIGITALIS; ESTROGEN DERIVATIVE; FRESH FROZEN PLASMA; GABEXATE MESILATE; GLYCERYL TRINITRATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NICOTINE; PROPYLENE GLYCOL; PROTAMINE SULFATE; QUININE; STREPTOKINASE; TETRACYCLINE DERIVATIVE; THROMBIN INHIBITOR;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CHILL; DRUG ADSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SAFETY; DYSPNEA; HEMODIALYSIS; HEPARINIZATION; HUMAN; LUNG EDEMA; MUSCLE CRAMP; NAUSEA; OPEN HEART SURGERY; PARTIAL THROMBOPLASTIN TIME; REVIEW; TASTE DISORDER; THROMBIN TIME; THROMBOCYTOPENIA; VERTIGO;

ANTICOAGULANTS; ANTITHROMBIN III; DRUG MONITORING; DRUG RESISTANCE; HEPARIN; HUMANS;

EID: 0141839719     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Hicks GL Jr. Heparin resistance during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1983;86:633.
2. Raschke RA, Guidry JR, Foley MR. Apparent heparin resistance from elevated factor VIII during pregnancy. Obstet Gynecol. 2000;96:804-806.
3. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg. 2000;70:873-877.
4. Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy: a controlled prospective trial. N Engl J Med. 1975;292:1046-1050.
5. Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
6. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg. 1994;57:1211-1216.
7. Cloyd GM, D'Ambra MN, Akins CW. Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1987;94:535-538.
8. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation, I: problems inherent in existing protocols. J Thorac Cardiovasc Surg. 1975;69:674-684.
9. Kaul TK, Crow MJ, Rajah SM, Deverall PB, Watson DA. Heparin administration during extracorporeal circulation. J Thorac Cardiovasc Surg. 1979;78:95-102.
10. Rosenberg RD, Bauer K.A, Marcum JA. Antithrombin III: the heparin-antithrombin system. Rev Hematol. 1986;2:351-416.
11. Murano G, Williams L, Miller-Andersson M. Some properties of antithrombin III and its concentration in human plasma. Thrombin Res. 1980;18:259-262.
12. Rosenberg RD. Action and interactions of antithrombin and heparin. N Engl J Med. 1975;292:146-151.
13. Mehraboon SI. Antithrombin concentrates in heparin resistant cardiopulmonary bypass patients. Clin Appl Thromb Hemost. 1996;2:103-106.
14. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RM, Carrell RW. The anticoagulant activation of anti-thrombin by heparin. Proc Natl Acad Sci USA. 1997;94:14683-14688.
15. Rosenberg RD, Bauer KA, Marcum JA. Antithrombin III: the heparin-antithrombin system. In: Murano G, ed. Reviews of Hematology: Protease Inhibitors of Human Plasma Biochemistry and Pathophysiology Target. Westbury, NY: PJD Publications; 1986:351-416.
16. College of American Pathologists. 1994 CAP Surveys, Set CG2-A. Northfield, IL: College of American Pathologists; 1994:5-19.
17. Hirsch J, Warkenitin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring efficacy, and safety. Chest. 1998;114:489S-510S.
18. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate. Thromb Res. 1976;8:413-416.
19. Samama MM. Laboratory monitoring of unfractionated heparin treatment. Clin Lab Med. 1995;15:109-117.
20. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation, II: the use of a dose response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685-689.
21. Mummaneni N, Istanbouli M, Pifarri R, El-Etr AA. Increased heparin requirements with autotransfusion. J Thorac Cardiovasc Surg. 1983;86:446-447.
22. Mabry CD, Read RC, Thompson BW, Williams GD, White HJ. Identification of heparin resistance during cardiac and vascular surgery. Arch Surg. 1979;114:129-134.
23. Weiss BM, Von Segesser LK, Turina MI, Seifert B, Pasch T. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low dose versus high dose heparin management. J Cardiothorac Vasc Anesth. 1996;10:464-470.
24. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978;26: 231-240.
25. Hunt B, Murkin J. Heparin resistance after aprotinin. Lancet. 1993;341:126.
26. White PW, Sadd JR, Nonsel RE. Thrombotic complications of heparin therapy. Ann Surg. 1979;190:595-608.
27. Kapsch D, Silver D. Heparin induced thrombocytopenia with thrombosis and hemorrhage. Arch Surg. 1981;116:1423-1427.
28. Ansell J, Deykin D. Heparin induced thrombocytopenia and recurrent thromboembolism. Am J Hematol. 1980;8:325-332.
29. Anderson EF. Heparin resistance prior to cardiopulmonary bypass. Anesthesiology. 1986;64:504-507.
30. Bode AP, Elick L. Lysed platelets shorten the activated coagulation time of heparinized blood. Am J Clin Pathol. 1989;91:430-434.
31. Williams CE, Entwistle MBP, Short PE. Platelet function tests: a critical review of methods. Med Lab Sci. 1985;42:262-274.
32. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg. 1997;85:498-506.
33. Irani MS. Antithrombin concentrates in heparin-resistant cardiopulmonary bypass patients. Clin Appl Thromb Hemost. 1996;2: 103-106.
34. Marciniak E, Gockerman JP. Heparin induced decrease in circulating antithrombin III. Lancet. 1977;2:581-584.
35. O'Brien JR, Etherington MD. Effect of heparin and warfarin on ATIII. Lancet. 1977;2:1232.
36. Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg. 2000;90:1076-1079.
37. Leong CK, Ong BC. A case report of HR due to acquired antithrombin III deficiency. Ann Acad Med Singapore. 1998;27:877-879.
38. Tanaka K, Takao M, Tada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Vasc Anesth. 1989;3:181-188.
39. Kaplan KL, Owen J. Plasma levels of platelet secretory proteins. Crit Rev Oncol Hematol. 1986;5:235s-255s.
40. Von Kaulla E, Von Kaulla KN. Antithrombin III and disease. Am J Clin Pathol. 1967;48:69-80.
41. Kauffmann RH, Veltkamp JJ, van Tilburg NH, et al. Acquired antithrombin III deficiency and thrombosis in the nephritic syndrome. Am J Med. 1978;65:607-613.
42. Bick RL. Clinical relevance of antithrombin III. Semin Thromb Haemost. 1982;8:276-287.
43. Winter JH, Fenech A, Ridley W, et al. Familial antithrombin III deficiency. Q J Med. 1982;51:373-395.
44. Nielsen LE, Bell WR, Borkon AM, Neill CA. Extensive thrombus formation with heparin resistance. Arch Intern Med. 1987;147:149-152.
45. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet. 1995;345:152-155.
46. O'Donnell J, Tuddenham EG, Manning R, et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997;77:825-828.
47. Kamphuisen PW, Eikenboom JC, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999; 81:680-683.
48. Denson KE. Ratio of factor VIII related antigen and factor VIII biological activity as an index of hypercoagulability and intravascular clotting. Thromb Res. 1977;10:107-119.
49. Pusineri F, Bisi A, Mussoni L, Remuzzi G, Donati MD. Intermittent heparin treatment does not induce hypercoagulability in hemodialyzed patients. J Clin Pathol. 1980;133:631-634
50. Mammaneni N, Istanbouli M, Piffare R, El-Etr AA. Increased heparin requirements with autotransfusions. J Thorac Cardiovasc Surg. 1983;86:446-447.
51. Hanwell ST, Kim YD, Rattan V, MacNamara TE. Increased heparin requirement with hypereosinophilic syndrome. Anesthesiology. 1981;55:450-452.
52. Anand S, Brimble S, Ginsberg J. Management of iliofemoral thrombosis in a pregnant patient with heparin resistance. Arch Intern Med. 1997;157:815-816.
53. Heparin. In: Physician's Desk Reference, 55th ed. Montvale, NJ: Medical Economics; 2001:3376.
54. Markarian M. Heparin resistance in newborn infants. J Pediatr. 1983;103:175.
55. Svehla C. Heparin resistance in patients with coronary artery disease. Atherosclerosis. 1973;18:509-512.
56. Chung F, David TE, Watt J. Excessive requirement for heparin during cardiac surgery. Can Anaesth Soc J. 1981;28:280-282.
57. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin. Arch Intern Med. 1987;147:857-860.
58. Col J, Col-Debeys C, Lavenne-Pardonge E, et al. Propylene glycol-induced heparin resistance during nitroglycerin infusion. Am Heart J. 1985;110:171-173.
59. Masato Y, Susumu O, Fred VL, et al. Heparin resistance during membrane plasmapheresis. Prog Clin Biol Res. 1990;337:367-370.
60. Fisher AR, Bailey CR, Shannon CN, Wielogorski AK. Heparin resistance after aprotinin. Lancet. 1992;340:1230-1231.
61. Christiansen J, Lindqvist B. Heparin-resistance in amyloidosis. Acta Med Scand. 1967;181:723-724.
62. Wickey GS, Keifer JC, Larach DR, Diaz MR, Williams DR. Heparin resistance after intraoperative platelet-rich plasma harvesting. J Thorac Cardiovasc Surg. 1992;103:1172-1176.
63. Jaques LB. Heparins: anionic polyelectrolyte drugs. Pharmacol Rev. 1980;31:99-166.
64. Boneu B, Caranobe C, Cadroy Y, et al. Pharmacokinetic studies of standard unfractionated heparin and low molecular weight heparins in the rabbit. Semin Thromb Hemost. 1988;14:18-27.
65. Edson JR, Krivit W, White JG. Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med. 1967;70:463-470.
66. Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 on assays of plasma heparin. Br J Haematol. 1984;57:585-596.
67. Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein: mechanism and role in the neutralization of heparin in plasma. J Biol Chem. 1983;258: 3803-3808.
68. Barzu T, van Rijn JLML, Petitou M, Molho P, Tobelem G, Caen JP. Endothelial binding sites for heparin: specificity and role in heparin neutralization. Biochem J. 1986;238:847-854.
69. van Rijn JLM, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells: implications for pharmacokinetics. Thromb Res. 1987;45:211-222.
70. Lane DA. Heparin binding and neutralizing proteins. In: Lane DA, Lindahl U, eds. Heparin, Chemical and Biological Properties: Clinical Applications. Boca Raton, Fla: CRC Press; 1989:363-391.
71. Leung L, Saigo K, Grant D. Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes: effect of histidine rich glycoprotein. Blood. 1989;73:177-184.
72. Talstad I. Heparin therapy adjusted for body weight. Am J Clin Pathol. 1985;83:378-381.
73. Lepor NE, Amin DK, Berberian L, Shah PK. Does nitroglycerin induce heparin resistance? Clin Cardiol. 1989;12:432-434.
74. Hunt BJ, Segal HC, Yacoub M. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1992;104: 211-272.
75. Korvald E, Abilgaar U, Fagerhol MK. Major operations, hemostatic parameters, and venous thrombosis. Thromb Res. 1974;4:147-154.
76. Rodzyneck JJ Lesutaud P, Damien J, et al. Evolution of antithrombin III during the postoperative period. Scand J Haematol. 1984; 33:207-211.
77. Von Kaulla E, Von Kaulla KN. Oral contraceptives and low antithrombin III activity. Lancet. 1970;1:36.
78. Ponari O, Corsi M, Manotti C, Pini M, Portioli D, Pod R. Predictive value of preoperative in vitro and in vivo studies for correct individual heparinization in cardiac surgery. J Thorac Cardiovasc Surg. 1979;78:87-94.
79. Ranucci M, Isgro G, Cazzaniga A, Soro G. Predictors of heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion. 1999;14:437-442.
80. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand fact or with age, race, sex and risk factors for atherosclerosis. Thromb Haemost. 1993;70:380-385.
81. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. Heparin resistance during cardiopulmonary bypass: the role of heparin pretreatment. J Thorac Cardiovasc Surg. 1983; 85:346-353.
82. Kanbak M. The treatment of heparin resistance with antithrombin II in cardiac surgery. Can J Anesth. 1999;46:581-585.
83. Horrow J. Management of coagulation and bleeding disorders. In: Kaplan JA, ed. Cardiac Anesthesia. 3rd ed. Philadelphia: WB Saunders; 1993:951-987.
84. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71:300-304.
85. Soloway HB, Christiansen TW. Heparin anticoagulation during cardiopulmonary bypass in antithrombin III deficient patient: implications relative to the etiology of heparin rebound. Am Soc Clin Pathol. 1980;73:723-725.
86. Sabbagh AH, Chung GK, Shuttleworth P, Applegate BJ, Gabriel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg. 1984;37:466-468.
87. Fairfax AJ, Ihbotson RM. Danazol raises antithrombin III levels in cases of familial deficiency. Lancet. 1984;1:1272-1273.